Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmanutra's score of 24 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pharmanutra reported total carbon emissions of approximately 1,151,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, primarily from purchased electricity, amounted to about 270,515 kg CO2e (market-based), while Scope 3 emissions, which include indirect emissions from business travel and employee commuting, totalled approximately 751,110 kg CO2e. Comparatively, in 2022, Pharmanutra's emissions were lower, with Scope 1 emissions at 199,150 kg CO2e and Scope 2 emissions at about 57,666 kg CO2e. The absence of Scope 3 data in 2022 indicates a significant increase in emissions reporting in 2023, particularly in the area of business travel, which accounted for 684,328 kg CO2e. Pharmanutra has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organisation, indicating that all reported figures are independently sourced from Pharmanutra S.p.A. Overall, Pharmanutra's commitment to addressing carbon emissions is evident through its comprehensive reporting, although further initiatives and targets would enhance its climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 | 
| Scope 2 | 39.72 | 00,000 | 00,000 | 000,000 | 
| Scope 3 | - | - | - | 000,000 | 
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 89% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmanutra has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
